2022
DOI: 10.1097/coc.0000000000000887
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer

Abstract: Objectives: Treatment with trastuzumab and chemotherapy significantly improves the outcome in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). CT-P6 (trastuzumab-pkrb; Herzuma) is a trastuzumab biosimilar approved for the treatment of HER2-positive gastric cancer. In this study, we aimed to compare the efficacy and safety of CT-P6 and reference trastuzumab as first-line treatment for HER2-positive AGC. Materials and Methods: … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
9
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 14 publications
0
9
0
Order By: Relevance
“…Five cohort studies of trastuzumab biosimilars were for breast cancer, while 1 was for gastric cancer . There were no significant differences in effectiveness and safety outcomes between the rituximab biosimilar group and the reference group (eTable 13 in Supplement 1).…”
Section: Resultsmentioning
confidence: 99%
See 4 more Smart Citations
“…Five cohort studies of trastuzumab biosimilars were for breast cancer, while 1 was for gastric cancer . There were no significant differences in effectiveness and safety outcomes between the rituximab biosimilar group and the reference group (eTable 13 in Supplement 1).…”
Section: Resultsmentioning
confidence: 99%
“…Of the 1195 records sourced from the database and manually searched, 49 studies met the inclusion criteria, including 39 RCTs 32-70 and 10 cohort studies. [71][72][73][74][75][76][77][78][79][80]…”
Section: Search Resultsmentioning
confidence: 99%
See 3 more Smart Citations